FAQ COVID-19 CRF

Read now
Current status: Report Completed
combacte-care

REJUVENATE

Testing aztreonam-avibactam to treat complicated intra-abdominal infections. A Phase II, pharmacokinetic and safety study of aztreonam-avibactam (ATM-AVI). This is a beta-lactam-beta lactamase inhibitor combination intended to treat serious Gram-negative bacterial infections in patients with limited or no treatment options.The trial was carried out in collaboration with Pfizer.

Testing ATM-AVI

REJUVENATE’s primary objective is to test ATM-AVI as a treatment for hospitalized patients with a complicated intra-abdominal infection. Secondary objectives include assessment of treatment outcome (proportion of patients with clinical cure at the TOC visit) and the relationship between exposure of ATM-AVI and clinical cure.

The proposed administration of ATM-AVI for enrolled patients was a loading dose, immediately followed by a maintenance infusion. From day two onwards, the dose was raised. This treatment was continued for five to fourteen days, deemed appropriate by the investigator. If the patients showed significant clinical improvement, all study therapies were discontinued. Assessment of clinical response was made at End-of-Treatment (EOT), Test-of-Cure Visit (TOC) and Late-Follow-Up (LFU) points.

Study information

REJUVENATE is a prospective, open-label, single-arm, dose-confirming multicenter study. The study was carried out in Spain, France and Germany. Forty adult patients with a diagnosis of complicated intra-abdominal infection and the need for a surgical intervention were enrolled. First a cohort of ten patients were assessed. When the safety and pharmacokinetic was confirmed, the study proceeded.

Study team members

  • Alison Luckey

    Study Physician / EFPIA leader / Pfizer

  • Angela Steinbach

    Project Manager / Academic / UKK Uniclinic Cologne

  • Barbara Evans

    EFPIA / Pfizer

Study level information

General information
  • Study NO N/A
  • Study Name REJUVENATE
  • Study Type Phase II
  • Study Status Database Lock
  • Enrollment Period 05/16 - 09/17
Enrollment
  • Total subjects planned 40
  • Total subjects screened 40
  • Total subjects enrolled 34
  • Total subjects completed 24

Study timeline

Light blue
Preparation phase
Dark blue
Trial period

Country level information

Filter
Sites planned 6
Sites activated 5
France
Subjects
planned
12
Subjects
enrolled
2
Subjects
completed
1
Subjects completed
8.3%
Sites planned 6
Sites activated 5
Germany
Subjects
planned
12
Subjects
enrolled
3
Subjects
completed
0
Subjects completed
0.0%
Sites planned 10
Sites activated 10
Spain
Subjects
planned
20
Subjects
enrolled
29
Subjects
completed
24
Subjects completed
120.0%
October 03, 2020

COMBACTE-CARE Project Update

April 05, 2020

COMBACTE-CARE Video

The multidisciplinary team of the Virgen del Rocío University Hospital in Seville – one of COMBACTE-CARE’s top recruiters in the Aztreonam...